Skip to main content
SpringerLink
Log in

Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine

  • Therapy in Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Cholinesterase inhibitors and memantine are the only classes of drugs approved for the treatment of dementia due to Alzheimer’s disease. This article provides evidence-based recommendations to address the issues regarding the use of cholinesterase inhibitors and memantine in clinical practice. It includes their efficacy, timing, assessment, use in institutionalized patients, combined use, and use in other dementia types. However, most of the studies are of short duration (<1 year) and are mainly focused on cognitive and global improvement, whereas the practical issue of their use in daily practice such as optimal duration of treatment, long-term efficacy and delaying institutionalization are limited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wilkinson D, Francis PT, Schwam E, Payne-Parrish J. Cholineserase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy. Drug Aging. 2004;21:453–78.

    Article  CAS  Google Scholar 

  2. Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3:211–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379–97.

    Article  PubMed  Google Scholar 

  4. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006. doi:10.1002/14651858.CD005593.

  5. Takeda A, Loveman E, Clegg A, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease. Int J Geriatr Psychiatry. 2006;21:17–28.

    Article  CAS  PubMed  Google Scholar 

  6. Perneczky R, Wagenpfeil S, Komosa K, et al. Mapping scores onto stages: mini-mental state examination and clinical dementia rating. Am J Geriatr Psychiatry. 2006;14:139–44.

    Article  PubMed  Google Scholar 

  7. Ritchie CW, Ames D, Clayton T. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease. Am J Geriatr Psychiatry. 2004;12:358–69.

    Article  PubMed  Google Scholar 

  8. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomized clinical trials. BMJ. 2005;331:321–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lanctôt KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. CMAJ. 2003;169:557–64.

    PubMed  PubMed Central  Google Scholar 

  10. Doody RS, Tariot PN, Pfeiffer E, Olin JT. Meta-analysis of six-month memantine trials in Alzheimer’s disease. Alzheimer’s Dement. 2007;3:7–17.

    Article  CAS  Google Scholar 

  11. Winblad B, Jones RW, Wirth Y, Stöffler A. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomized clinical trials. Dement Geriatr Cogn Disord. 2007;24:20–7.

    Article  CAS  PubMed  Google Scholar 

  12. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006. doi:10.1002/14651858.CD003154.pub5.

  13. Doraiswarmy PM, Kaiser L, Bicher F, et al. The Alzheimer’s Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive declines in multicenter clinical trials of mild-to-moderate Alzheimer’s disease. Alzheimer Dis Assoc Disord. 2001;15:174–83.

    Article  Google Scholar 

  14. Qaseem A, Snow Cross JT, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148:370–8.

    Article  PubMed  Google Scholar 

  15. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate Alzheimer’s disease. Neurology. 2001;57:489–95.

    Article  CAS  PubMed  Google Scholar 

  16. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of functional survival study of donepezil in Alzheimer’s disease patients. Neurology. 2001;57:481–8.

    Article  CAS  PubMed  Google Scholar 

  17. Coutrtney C, Farrell D, Gray R, AD2000 Collaborative Group, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomized double-blind trials. Lancet. 2004;363:2105–15.

    Article  Google Scholar 

  18. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioural and psychological symptoms of dementia in Alzheimer’s disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigamine and galtantamine. Int Psychogeriatr. 2009;21:813–24.

    Article  PubMed  Google Scholar 

  19. Schneider LS, Dagerman KS, Higgins JPT, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer’s disease. Arch Neurol. 2011;68:991–8.

    Article  PubMed  Google Scholar 

  20. Wilkinson D, Wirth Y, Goebel C. Memantine in patients with moderate to severe Alzheimer’s disease: meta-analysis using realistic definitions of response. Dement Geriatr Cogn Disord. 2014;37:71–85.

    Article  CAS  PubMed  Google Scholar 

  21. Wilkinson D. A review of the effects of memantine on clinical progression in Alzheimer’s disease. Int J Geriatr Psychaitry. 2012;27:769–76.

    Article  Google Scholar 

  22. Atri A, Shaughnessy BS, Locascio JJ, Growdon JH. Long term course and effectiveness of combination therapy in Alzheimer’s disease. Alzheimer Dis Assoc Disord. 2008;22:209–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lopez OL, Becker JT, Wahed AS, et al. Long term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2009;80:600–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Wilock GK, Lilienfeld S, Gaens E, et al. Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer’s disease: multicentre randomized controlled trial. BMJ. 2000;321:1445.

    Article  Google Scholar 

  25. Kim JM, Shin IS, Yoon JS. Correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer’s disease. Int Psychogeriatr. 2002;14:187–95.

    Article  PubMed  Google Scholar 

  26. Wallin AK, Hansson O, Blennow K, et al. Can csf biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer’s disease? Int J Geriatr Psychiatry. 2009;24:638–47.

    Article  CAS  PubMed  Google Scholar 

  27. Ohnishi T, Sakiyama Y, Kimura Y, et al. The predication of response to galantamine treatment in patients with mild to moderate Alzheimer’s disease. Curr Alzheimer Res. 2014;11:110–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Babiloni C, Cassetta E, Dal Forno G, et al. Donepezil effects on sources of cortical rhythm in mild Alzheimer’s disease: responders vs. non-responders. Neuroimage. 2006;15:1650–5.

    Article  Google Scholar 

  29. Ngo J, Holroyad-Leduc JM. Systematic review of recent dementia practice guidelines. Age Ageing. 2015;44:25–33.

    Article  PubMed  Google Scholar 

  30. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry. 2003;11:131–45.

    Article  PubMed  Google Scholar 

  31. Doraiswamy PM, Krishnan RR, Anand R, et al. Long-term effects of rivastigmine in moderately severe Alzheimer’s disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:705–12.

    Article  CAS  PubMed  Google Scholar 

  32. Herrmann N, Lanctôt KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the diagnosis and Treatment of Dementia 2012. Alzheimer’s Res Ther. 2013;5:S5. doi:10.1186/alzrt201.

    Article  Google Scholar 

  33. Hogan DB, Bailey P, Black S, et al. Diagnosis and treatment of dementia: 5. Non-pharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ. 2008;179:1019–26.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Full prescription information. Aricept (donepezil). www.labeling.pfizer.com/ShowLabeling.aspx?id=510. Accessed May 2016

  35. Full prescription information. Exelon (rivastigmine). https://www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf. Assessed May 2016

  36. Full prescription information. Razadyne (galantamine). https://www.janssenmd.com/pdf/razadyne/PI-Razadyne-RazadyneER.pdf. Assessed May 2016

  37. Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169:867–73.

    Article  PubMed  Google Scholar 

  38. Wilkinson D, Doody R, Helme R, Donepezil 308 Study Group, et al. Donepezil 308 Study Group. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61:479–86.

    Article  CAS  PubMed  Google Scholar 

  39. Black S, Roman GC, Geldmacher DS, Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24 week, multicentre, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34:2323–30.

    Article  CAS  PubMed  Google Scholar 

  40. Reikin NR, Reichman WE, Orazem J, McRae T. A large community based, open-label trial of donepezil in the treatment of Alzheimer’s disease. Dement Geri Cogn Disord. 2003;16:15–24.

    Article  Google Scholar 

  41. Agronin ME. Alzheimer’s disease and other dementia: a practical guide. 3rd ed. New York: Routeledge; 2014.

    Google Scholar 

  42. Winblad B, Grossberg G, Frölich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of first skin patch for Alzheimer’s disease. Neurology. 2007;69:S14–22.

    Article  CAS  PubMed  Google Scholar 

  43. Cumming JL, Farlow MR, Meng X, Tekin S, Olin JT. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild to moderate Alzheimer’s disease. Clin Drug Investig. 2010;30:41–9.

    Article  Google Scholar 

  44. Full prescribing Information. Namenda (memantine). http://pi.actavis.com/data_stream.asp?product_group=1901&p=pi&language=E. Assessed May 2016

  45. Bowie P, Branton T, Holmes J. Should the mini mental state examination to be used to monitor dementia treatments? Lancet. 1999;354:1527–8.

    Article  CAS  PubMed  Google Scholar 

  46. Franco-Marina F, Garcia-González JJ, Wagner-Echeagaray F, et al. The mini-mental state examination revisited : ceiling and floor effects after score adjustment for educational level in an aging Mexican population. Int Psychogeratr. 2010;22:72–81.

    Article  Google Scholar 

  47. Holmes C, Lovestone S. Long-term cognitive and functional decline in late onset Alzheimer’s disease: therapeutic implications. Age Ageing. 2003;32:200–4.

    Article  PubMed  Google Scholar 

  48. NICE Technology appraisal guidance TA 217. Alzheimer’s disease—donepezil, galantemine, rivastigmine and memantine for the treatment of Alzheimer’s disease. National Institute for Hleath and Clinic Excellence 2011. http://www.nice.org.uk/guidance/ta217/resources/donepezil-galantamine-rivastigmine-and-memantine-for-the-treatment-of-alzheimers-disease-82600254699973. Assessed May 2016

  49. Herrmann N, Gauthier S. Diagnosis and treatment of dementia: 6. Management of severe Alzeimer’s disease. CMAJ. 2008;179:1279–87.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alheimer’s disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994;151:390–6.

    Article  CAS  PubMed  Google Scholar 

  51. Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. Screening for dementia in primary care: a summary of the evidence for the U.S. preventive services task force. Ann Inten Med. 2003;138:927–37.

    Article  Google Scholar 

  52. Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry. 2006;14:561–72.

    Article  PubMed  Google Scholar 

  53. Auriacombe S, PereJ-J Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alaheimer’s disease who failed to benefit from treatment with donepezi. Curr Med Res Opin. 2002;18:129–38.

    Article  CAS  PubMed  Google Scholar 

  54. Ferris SH. Switching previous therapies for Alzheimer’s disease to galantamine. Clin Ther. 2001;23:A3–7.

    Article  CAS  PubMed  Google Scholar 

  55. Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19:707–14.

    Article  PubMed  Google Scholar 

  56. Muayquil T, Camicioli R. Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer’s disease and other dementias. Demnt Geriatr Cogn Disord Extra. 2012;2:546–72.

    Article  Google Scholar 

  57. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alheimer’s disease: a systematic review. BMJ Open. 2012;2:e000917. doi:10.1136/bmjopen-2012-000917.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Matsunaga S, Kishi T, Iwata N. Comincation therapy with cholinesterase inhibitors and mematnine of Alzheimer’s disease: a systematic review and meta-analysis. Int J Neuropsychopharmcol. 2015;18:pyu115.

    Article  Google Scholar 

  59. Atri A, Molinuevo JL, Lemming O, et al. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5:6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366:893–903.

    Article  CAS  PubMed  Google Scholar 

  61. Herrmann N, Black SE, Li A, Lanctôt KL. Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts. Int Psychogeriatr. 2011;23:539–45.

    Article  PubMed  Google Scholar 

  62. Farlow M, Cummings JL. Effective pharmacologic management of Alzheimer’s disease. Am J Med. 2007;120:388–97.

    Article  CAS  PubMed  Google Scholar 

  63. Tarior PN, Cummings JL, Katz IR, et al. A randomised, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatrc Soc. 2001;49:1590–9.

    Article  Google Scholar 

  64. Winblad B, Kilander L, Erikson S, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006;367:1057–65.

    Article  CAS  PubMed  Google Scholar 

  65. Lee J, Monette J, Sourial N, Monette M, Bergman H. The use of a cholinesterase inhibitor review committee in long-term care. J Am Med Dir Assoc. 2007;8:243–7.

    Article  PubMed  Google Scholar 

  66. Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrance Database Syst Rev. 2012. doi:10.1002/14651858.CD009132.pub2.

  67. Tricco AC, Soobiah C, Berliner S, et al. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systemic review and meta-analysis. CMAJ. 2013;185:1393–401.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Schneider LS, Insel PS, Weiner M. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer’s disease neuroimaging initiative. Arch Neurol. 2011;68:58–66.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Schneider LS. The potential limit for clinical trials for early Alzheimer’s disease and some recommendations. J Nutr Health Aging. 2010;14:295–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a mete-analysis of randomized controlled trials. Lancet Neurol. 2007;6:782–92.

    Article  CAS  PubMed  Google Scholar 

  71. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and Cognitive impairment in Parkinson’s disease. Cochrane Datebase Syst Rev. 2012;3:CD006504.

    Google Scholar 

  72. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson’s disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004;17:164–71.

    Article  PubMed  Google Scholar 

  73. Mori E, Ikeda M, Kosaka K, Donepezil-DLB study investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo controlled trial. Ann Neurol. 2012;72:42–52.

    Article  Google Scholar 

  74. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8:6–13.

    Article  Google Scholar 

  75. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine of patients with Parkinson’s disease or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:969–77.

    Article  CAS  PubMed  Google Scholar 

  76. Wesnes KA, Aarsland D, Ballard C, Londos E. Memantine improves attention and episodic memory in Parkinson’s disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2015;30:46–54.

    Article  PubMed  Google Scholar 

  77. Kerchner GA, Tartaglia MC, Boxer AL. Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia. Expert Rev Neurother. 2011;11:709–17.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Boxer AL, Knopman DS, Kaufer DI, Grossman M, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:149–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Rafii MS, Aisen P. Advances in Alzheimer’s disease drug development. BMC Med. 2015;13:62.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Geriatrics, Caritas Medical Centre, Hong Kong, China

    Chit Wai Wong

Authors
  1. Chit Wai Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chit Wai Wong.

Ethics declarations

Funding

No funding was received for the preparation of this review.

Conflict of interest

Dr Wong has no conflicts of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wong, C.W. Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine. Drugs Aging 33, 451–460 (2016). https://doi.org/10.1007/s40266-016-0372-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-016-0372-3

Keywords

Search

Navigation